Structures by: Oswald I. D.
Total: 194
C4H6O2
C4H6O2
The journal of physical chemistry. B (2015) 119, 36 12147-12154
a=3.6140(7)Å b=16.420(3)Å c=6.773(3)Å
α=90° β=90.36(3)° γ=90°
P-aminobenzoic acid
C7H7NO2
CrystEngComm (2019) 21, 13 2058
a=6.4341(11)Å b=4.6151(3)Å c=10.5313(7)Å
α=90° β=100.730(10)° γ=90°
P-aminobenzoic acid
C7H7NO2
CrystEngComm (2019) 21, 13 2058
a=6.4003(11)Å b=4.5981(4)Å c=10.4452(15)Å
α=90° β=100.748(14)° γ=90°
P-aminobenzoic acid
C7H7NO2
CrystEngComm (2019) 21, 13 2058
a=6.4342(10)Å b=4.6146(4)Å c=10.5397(10)Å
α=90° β=100.667(9)° γ=90°
4-aminobenzoic acid
C7H7NO2
CrystEngComm (2019) 21, 13 2058
a=6.5086(5)Å b=4.6661(4)Å c=10.7596(8)Å
α=90° β=100.6850(10)° γ=90°
Paracetamol
C8H9NO2
CrystEngComm (2019) 21, 30 4437
a=17.143(8)Å b=11.806(6)Å c=7.399(10)Å
α=90° β=90° γ=90°
Paracetamol
C8H9NO2
CrystEngComm (2019) 21, 30 4437
a=17.1202(17)Å b=11.7968(11)Å c=7.288(2)Å
α=90° β=90° γ=90°
Paracetamol:methanol solvate, (1:1)
CH4O,C8H9NO2
CrystEngComm (2019) 21, 30 4437
a=12.9717(15)Å b=17.1881(9)Å c=13.0437(19)Å
α=90° β=116.032(8)° γ=90°
Acetaminophen
C8H9NO2
CrystEngComm (2019) 21, 30 4437
a=17.1522(5)Å b=11.8201(4)Å c=7.3985(2)Å
α=90° β=90° γ=90°
Paracetamol:methanol solvate, (1:1)
CH4O,C8H9NO2
CrystEngComm (2019) 21, 30 4437
a=13.0234(15)Å b=17.2078(9)Å c=13.0925(15)Å
α=90° β=116.209(7)° γ=90°
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=7.1314(2)Å b=10.4809(2)Å c=16.7109(4)Å
α=80.5779(12)° β=86.4941(12)° γ=79.2821(12)°
?1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=6.7888(3)Å b=9.6045(11)Å c=16.3703(16)Å
α=77.764(8)° β=84.858(6)° γ=81.297(8)°
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=6.7561(3)Å b=9.5308(11)Å c=16.3385(16)Å
α=77.508(8)° β=84.710(6)° γ=81.556(8)°
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=6.7109(4)Å b=9.4367(12)Å c=16.2988(17)Å
α=77.132(9)° β=84.534(7)° γ=81.962(9)°
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=6.9301(4)Å b=9.9420(7)Å c=16.514(3)Å
α=79.013(11)° β=85.441(10)° γ=80.339(5)°
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=7.0133(6)Å b=10.155(2)Å c=16.607(3)Å
α=79.683(14)° β=85.829(11)° γ=79.844(14)°
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1,2-benzisothiazol-3(2H)-one 1,1-dioxide
C19H16ClNO4,C7H5NO3S
CrystEngComm (2019) 21, 30 4465
a=6.6623(3)Å b=9.3453(11)Å c=16.2637(15)Å
α=76.764(8)° β=84.331(6)° γ=82.375(8)°
Paracetamol monomethanolate
C9H13N1O3
Chemical Communications (Cambridge, United Kingdom) (2003) 24 3004-3005
a=7.630(2)Å b=17.209(3)Å c=7.3710(11)Å
α=90° β=115.52(3)° γ=90°
C3H6N6O6
C3H6N6O6
Chemical communications (Cambridge, England) (2010) 46, 31 5662-5664
a=7.0324(11)Å b=10.530(3)Å c=8.7909(11)Å
α=90° β=90° γ=90°
2-methylphenol
C7H8O
CrystEngComm (2009) 11, 3 463
a=5.9637(4)Å b=4.7006(3)Å c=19.769(3)Å
α=90.00° β=92.792(10)° γ=90.00°
2-Chlorophenol
C6H5ClO
CrystEngComm (2009) 11, 3 463
a=5.5826(10)Å b=9.587(3)Å c=10.054(4)Å
α=90.00° β=96.19(2)° γ=90.00°
2-methylphenol
C7H8O
CrystEngComm (2009) 11, 3 463
a=16.4153(2)Å b=16.4153(2)Å c=5.7931(2)Å
α=90.00° β=90.00° γ=120.00°
(0.45)2-METHYLPHENOL:(0.55)2-CHLOROPHENOL
0.45(C7H8O)0.55(C6H5OCl)
CrystEngComm (2009) 11, 3 463
a=16.1628(2)Å b=16.1628(2)Å c=5.9006(1)Å
α=90.00° β=90.00° γ=120.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=14.992(2)Å b=6.4333(7)Å c=13.610(2)Å
α=90.00° β=107.306(12)° γ=90.00°
Bis(N,N-Dimethylurea) & oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.740(5)Å b=6.440(5)Å c=13.540(5)Å
α=90.00° β=110.880(10)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.770(5)Å b=6.440(5)Å c=13.600(5)Å
α=90.00° β=111.140(10)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.7944(3)Å b=6.4482(2)Å c=13.6550(6)Å
α=90.00° β=111.407(2)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.820(5)Å b=6.450(5)Å c=13.710(5)Å
α=90.00° β=111.660(10)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.790(5)Å b=6.450(5)Å c=13.660(5)Å
α=90.00° β=111.410(10)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.840(5)Å b=6.460(5)Å c=13.770(5)Å
α=90.00° β=111.940(10)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.870(5)Å b=6.470(5)Å c=13.830(5)Å
α=90.00° β=112.200(10)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C4H9N2O3
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.8936(4)Å b=6.4695(3)Å c=13.8871(7)Å
α=90.00° β=112.474(3)° γ=90.00°
Bis(N,N-Dimethylurea) oxalic acid
C8H18N4O6
Physical chemistry chemical physics : PCCP (2012) 14, 38 13273-13283
a=7.890(5)Å b=6.470(5)Å c=13.890(5)Å
α=90.00° β=112.470(10)° γ=90.00°
Cyclotrimethylene-trinitramine
C3H6N6O6
CrystEngComm (2008) 10, 2 162
a=12.5650(19)Å b=9.4769(6)Å c=10.9297(9)Å
α=90° β=90° γ=90°
Cyclotrimethylene-trinitramine
C3N6O6D6
CrystEngComm (2008) 10, 2 162
a=12.6319(15)Å b=9.5554(14)Å c=11.0036(22)Å
α=90.0° β=90.0° γ=90.0°
2:1:2 Paracetamol:piperazine:ethanol solvate
C8H9NO2,0.5(C4H10N2),C2H6O
CrystEngComm (2008) 10, 9 1114
a=7.544(5)Å b=8.604(7)Å c=10.394(3)Å
α=93.18(5)° β=97.73(4)° γ=114.70(5)°
C4H6O2
C4H6O2
CrystEngComm (2011) 13, 14 4503
a=3.8056(3)Å b=10.4842(8)Å c=11.6286(10)Å
α=90° β=91.468(4)° γ=90°
C3H4O2
C3H4O2
CrystEngComm (2011) 13, 14 4503
a=5.1352(10)Å b=9.802(3)Å c=6.850(4)Å
α=90° β=97.28(3)° γ=90°
C4H6O2
C4H6O2
CrystEngComm (2011) 13, 14 4503
a=3.8808(11)Å b=10.616(6)Å c=11.718(4)Å
α=90° β=91.24(2)° γ=90°
C4H6O2
C4H6O2
CrystEngComm (2011) 13, 14 4503
a=3.7643(13)Å b=13.501(6)Å c=8.308(5)Å
α=90° β=101.22(3)° γ=90°
C12H20N14O14
C12H20N14O14
CrystEngComm (2012) 14, 10 3742
a=7.7843(16)Å b=12.857(3)Å c=13.002(3)Å
α=113.73(3)° β=106.34(3)° γ=92.43(3)°
2,4,6,8,10,12-hexanitrohexaazaisowurtzitane:
C13.33H15.67N16O18.67
CrystEngComm (2012) 14, 10 3742
a=15.7503(9)Å b=20.5096(13)Å c=23.2073(13)Å
α=90° β=90.092(2)° γ=90°
2,4,6,8,10,12-hexanitrohexaazisowurtzitane:
C24H60N21O15P3
CrystEngComm (2012) 14, 10 3742
a=18.8930(3)Å b=12.07295(13)Å c=21.8241(4)Å
α=90° β=114.977(2)° γ=90°
2,4,6,8,10,12-hexanitrohexaazaisowurtzitane: 1,4-dioxane (1:4) Co-crystal
C10H17N6O9.50
CrystEngComm (2012) 14, 10 3742
a=10.3061(3)Å b=10.7691(3)Å c=14.5298(4)Å
α=73.897(2)° β=89.527(2)° γ=85.057(2)°
N-Phenyl-p-phenylenediamine+diglycolic acid
C12H12N2,C4H6O5
CrystEngComm (2016) 18, 28 5360
a=17.9195(15)Å b=9.1323(8)Å c=18.7653(15)Å
α=90° β=90° γ=90°
N-Phenyl-p-phenylenediamine+diglycolic acid
C12H12N2,C4H6O5
CrystEngComm (2016) 18, 28 5360
a=19.0949(19)Å b=9.2904(9)Å c=17.9875(19)Å
α=90° β=110.543(5)° γ=90°
1,4-Diaminobenzene+lawsone
2(C10H5O3),C6H10N2
CrystEngComm (2016) 18, 28 5360
a=14.204(3)Å b=8.573(2)Å c=8.3934(19)Å
α=90° β=91.851(13)° γ=90°
1,4-Diaminobenzene+sebacic acid
C10H16O4,2(C6H9N2)
CrystEngComm (2016) 18, 28 5360
a=9.1366(7)Å b=6.2639(6)Å c=20.6631(16)Å
α=90.00° β=94.489(5)° γ=90.00°
1,4-Diaminobenzene+trimesic acid+methanol
C9H5O6,C6H9N2,CH4O
CrystEngComm (2016) 18, 28 5360
a=3.9902(2)Å b=17.0520(9)Å c=23.5518(12)Å
α=90° β=90° γ=90°
4-aminobenzoic acid
C7H7NO2
CrystEngComm (2019) 21, 13 2058
a=6.4551(5)Å b=4.6740(4)Å c=10.5470(9)Å
α=90° β=100.754(3)° γ=90°
Nitric acid
H1N1O3
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3736-3743
a=6.3689(3)Å b=8.6046(4)Å c=16.4141(9)Å
α=90° β=90.055(4)° γ=90°
Nitric acid
H1N1O3
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3736-3743
a=6.3031(2)Å b=8.5847(2)Å c=16.3122(4)Å
α=90° β=90.039(2)° γ=90°
H1N1O3
H1N1O3
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3736-3743
a=7.3163(4)Å b=8.4176(11)Å c=7.3135(11)Å
α=90° β=116.895(6)° γ=90°
Paracetamol monomethanolate
C9H13N1O3
Chemical Communications (Cambridge, United Kingdom) (2003) 24 3004-3005
a=7.630(2)Å b=17.209(3)Å c=7.3710(11)Å
α=90° β=115.52(3)° γ=90°
Beta-1,3,5-trinitrohexahydro-1,3,5-triazine
C3H6N6O6
Chemical communications (Cambridge, England) (2009) 34, 5 562-564
a=15.0972(7)Å b=7.5463(4)Å c=14.4316(6)Å
α=90° β=90° γ=90°
Beta-1,3,5-trinitrohexahydro-1,3,5-triazine
C3H6N6O6
Chemical communications (Cambridge, England) (2009) 34, 5 562-564
a=15.1267(11)Å b=7.4563(6)Å c=14.3719(11)Å
α=90° β=90° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0093(3)Å b=22.8207(8)Å c=10.4016(4)Å
α=90° β=91.416(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1345(7)Å b=23.048(3)Å c=7.4330(8)Å
α=90° β=90.449(6)° γ=90°
30:70 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.72(Br),0.28(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.2017(6)Å b=22.3376(13)Å c=10.5639(6)Å
α=90° β=90.157(3)° γ=90°
Alpha lipoicacid nicotinamide co-crystal
C8H14O2S2,C6H6N2O
CrystEngComm (2014) 16, 26 5769
a=26.292(2)Å b=5.2948(4)Å c=34.158(3)Å
α=90.00° β=90.598(4)° γ=90.00°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0604(18)Å b=22.876(4)Å c=10.4041(19)Å
α=90° β=91.741(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=9.9973(13)Å b=22.788(3)Å c=10.4078(14)Å
α=90° β=91.2430(10)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1160(12)Å b=22.916(4)Å c=7.3818(13)Å
α=90° β=91.415(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1234(14)Å b=22.966(4)Å c=7.3986(14)Å
α=90° β=91.146(2)° γ=90°
(+-)-4'-methylmethcathinone hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1264(14)Å b=22.986(5)Å c=7.4072(14)Å
α=90° β=90.974(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1314(14)Å b=23.013(5)Å c=7.4180(15)Å
α=90° β=90.803(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1365(14)Å b=23.041(5)Å c=7.4304(15)Å
α=90° β=90.628(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=5.7804(4)Å b=19.7971(14)Å c=10.5967(6)Å
α=90° β=100.841(3)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=10.8355(19)Å b=10.2030(17)Å c=11.5425(19)Å
α=90° β=111.839(8)° γ=90°
60:40 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.4(Br),0.6(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.1409(11)Å b=22.488(3)Å c=10.4979(11)Å
α=90° β=90.359(8)° γ=90°
70:30 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16Br0.30Cl0.70N1O1
CrystEngComm (2014) 16, 26 5827
a=10.1012(5)Å b=22.5506(12)Å c=10.4737(5)Å
α=90° β=90.441(3)° γ=90°
1,4-Dioxane-2,5-dione
C4H4O4
CrystEngComm (2015) 17, 8 1778
a=6.7039(2)Å b=14.9481(4)Å c=9.6177(2)Å
α=90° β=98.9365(18)° γ=90°
1,4-Dioxane-2,5-dione
C4H4O4
CrystEngComm (2015) 17, 8 1778
a=5.2399(2)Å b=7.4388(3)Å c=11.7763(4)Å
α=90° β=90° γ=90°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.8746(14)Å b=6.4011(10)Å c=8.980(3)Å
α=74.05(2)° β=83.54(2)° γ=80.468(18)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.835(3)Å b=6.310(2)Å c=8.895(7)Å
α=74.62(4)° β=84.12(5)° γ=80.67(4)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.760(2)Å b=6.1455(12)Å c=8.737(4)Å
α=76.06(3)° β=84.56(3)° γ=81.25(2)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.728(2)Å b=6.0501(14)Å c=8.684(5)Å
α=76.54(3)° β=84.73(4)° γ=81.67(3)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.693(2)Å b=5.9013(14)Å c=8.599(5)Å
α=77.48(3)° β=84.97(4)° γ=82.35(3)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.676(3)Å b=5.8115(17)Å c=8.543(6)Å
α=77.95(4)° β=85.11(5)° γ=82.77(4)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.5100(5)Å b=5.9287(6)Å c=8.503(3)Å
α=76.528(16)° β=85.624(17)° γ=83.203(8)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.4832(4)Å b=5.8932(4)Å c=8.465(2)Å
α=76.234(13)° β=85.836(13)° γ=83.284(6)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.4609(4)Å b=5.8592(5)Å c=8.427(2)Å
α=75.991(15)° β=86.055(14)° γ=83.349(6)°
Quinol:pyrazine
C6H6O2.C4H4N2
Acta Crystallographica Section B (2005) 61, 1 46-57
a=8.901(3)Å b=7.666(2)Å c=6.984(2)Å
α=90.00° β=90.091(6)° γ=90.00°
Quinol:piperazine
C4H10N2,C6H6O2
Acta Crystallographica Section B (2005) 61, 1 46-57
a=5.7060(15)Å b=6.7599(19)Å c=7.0771(18)Å
α=100.269(4)° β=112.446(3)° γ=90.163(3)°
Quinol:2Morpholine
2(C4H9NO)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=6.6652(13)Å b=5.5881(11)Å c=20.034(4)Å
α=90.00° β=94.942(4)° γ=90.00°
Hemi-quinol pyridine adduct
C3H3O(C5H5N)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=6.4990(9)Å b=16.459(2)Å c=7.1794(10)Å
α=90.00° β=112.986(3)° γ=90.00°
Quinol:2(4,4'-bipyridine)
2(C10H8N2)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=7.820(4)Å b=8.619(4)Å c=9.201(4)Å
α=111.897(7)° β=109.851(7)° γ=94.657(8)°
Quinol:2(N-methylmorpholine)
2(C5H11NO)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=6.9612(10)Å b=7.3146(11)Å c=9.659(2)Å
α=106.182(3)° β=104.481(3)° γ=106.201(2)°
Quinol:dimethylpiperazine
C6H14N2.C6H6O2
Acta Crystallographica Section B (2005) 61, 1 46-57
a=8.9620(8)Å b=9.4944(8)Å c=14.7119(13)Å
α=90.501(2)° β=92.919(2)° γ=99.664(2)°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=5.6510(12)Å b=5.0642(10)Å c=9.3185(19)Å
α=90° β=107.518(4)° γ=90°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=5.6747(9)Å b=5.0760(4)Å c=9.4753(13)Å
α=90° β=107.832(11)° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=3.9846(5)Å b=13.9272(19)Å c=20.699(3)Å
α=90° β=90° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=4.0949(4)Å b=13.875(3)Å c=20.716(3)Å
α=90° β=90° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=8.7086(11)Å b=15.4523(19)Å c=8.7414(11)Å
α=90° β=93.954(2)° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=3.9724(5)Å b=12.7328(17)Å c=23.155(3)Å
α=90° β=94.126(2)° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=4.1096(4)Å b=12.7665(10)Å c=23.181(3)Å
α=90° β=94.201(14)° γ=90°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=5.7168(7)Å b=9.9997(19)Å c=17.868(2)Å
α=90° β=90° γ=90°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=17.1336(10)Å b=8.2766(5)Å c=11.4975(7)Å
α=90° β=100.234(2)° γ=90°
Paracetamol hemi-dimethylpiperazine
2[C8H9NO2][C6H14N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=10.6970(9)Å b=11.0240(9)Å c=9.4896(8)Å
α=90.00° β=100.684(2)° γ=90.00°